Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirzepatide in Individuals With Alcohol Use Disorder and Metabolic Alcohol-associated Liver Disease
NCT07046819Phase 2Recruiting
- Sponsor
- National Institute on Alcohol Abuse and Alcoholism
- Start
- Jun 2026
- Primary completion
- Jul 2027
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in alcohol use disorder (AUD) and metabolic alcohol-associated liver disease (MetALD) comparing Tirzepatide with Placebo (2 arms). Primary endpoint: Metabolic improvement from baseline at 12 weeks. Started Jun 2026; status: recruiting.
02
Drugs
03
Conditions
alcohol use disorder (AUD)metabolic alcohol-associated liver disease (MetALD)
Beyond the preview
Go deeper on NCT07046819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07046819.